Services Design Development Scientific Advice Project Management QA – Quality Assurance Monitoring Clinical Performance Data Management/eTrials Biostatistics Medical Writing Expert Statement Expertise Pharmacokinetics BA/BE Interactions Oncological trials Ophthalmological trials Inhalatives Transdermal Therapeutic Systems Children Sexual Hormones Therapeutic Expertise Clinical Development Phase I Phase II / Proof of Concept Phase III in OTC Phase III Non-Interventional Magnetic Marker Monitoring Medical Devices Nutrition Studies Clinical Pharmacology Unit Location Plan Capacity Technical Monitoring Ophthalmology Gynaecology Intensive Assessment Unit Clean Room Area Archive About Us Goals and Visions Our Experts Science Quality Library Presentations Library Publications Locations Career News EUFEPS Network on Dermatopharmacy just founded 22nd PKPD Expertentreffen in the heart of the Black Forest 3rd GBHI in Amsterdam: lively discussions and intensive exchange with authorities Meet us in Amsterdam: 3rd GBHI Conference starts soon (12 – 13 April 2018) Meet us in Munich: AGAH Annual Meeting 26 – 27 April 2018 Regorafenib: first in human as eye drops Probanden The SocraTec Family SocraTec C&S SocraMetrics Cooperations
Rhine Main area Contraception Training Early phase Copyright Monitoring Phase IIa trials Biopharmaceutics Pharmacodynamic studies HTA PAES Competence FIM Creativity Phase II Edema Sample size estimation Uveitis Feasibility Paediatricians Recruitment rates Ophthalmology US CFR 21 Part 11 Common cold Consultancy Lung Asthma Clinical pharmacology unit US FDA ICF CDM ANVISA Clinical Monitoring Absorption Hormone replacement therapy Endpoint Non interventional Inspection IVIVC DUS Dry eye GCP training SocraTec C&S Elpro Pulse oximetry plethysmography GLP Investigators brochure Hypothalamic Absorption windows Patient recruitment Statistical programming Biosimilars Transdermal therapeutic system Phase I Cough TTS Data Validation Plan Thuringia Network Local tolerability Sore throat Ocular tolerability Gynaecological trials Glaucoma SOP based Efficacy Pharmacokinetics Oncologic network Phase I Unit Clinical development program Sensitisation trials Allergy Immunogenicity DPI Healthy subjects Slit lamp microscopy Highly variable drugs Intensive assessment station Safety Oncological patients Good Clinical Practice Statistical services Quality ADAM Quality Assurance PASS Source Data Verification Ophthalmological trials Data management Sequential designs Children MDI Scientific advice HRT CDSIC Protocol Project Management Product development Bioequivalence Female adolescents Referral system Scientific expertise Experience Ovulation inhibition Data Management Plan Central surveillance system Phase IV FDA Centralised procedure Axis Patch adhesion Macular Cardiovascular surveillance CRO CDASH Protocol development IB SAS Phase IIb trials NIS Biopharmaceutical Degeneration Standardisation Anaesthesiologist Pituitary EMA AGAH Subcontractor qualification IEC Inhalatives Audit First in human Pharmacokintetics Drug Drug Interaction Pilot study Spacious archive Phase III DFI HPA axis CRF Xerostomia Steady state MMM Quality Management System In vitro in vivo correlation Legal Information Biometrics OTC Dose linearity Post authorisation IMPD Authorities Life cycle management Patch Statistical Analysis Plan Database Patients DDI Dry powder inhaler CDISC Ophthalmologist Metered dose inhaler Standard operating procedure Clinical trials Eye disease Legal representative Clinical study Oncology GCP SDV Informed Consent Procedure CRA Adrenocortical Bioavailability MCID Pragmatism Drug Food Interaction Charcoal COPD Dermal irritation Design development Postmenopausal women Auditing Expert WinNonlin Pharmacology  
 
Menu

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All fine on front page